Saad Z. Usmani, MD, clinical professor of medicine, UNC-Chapel Hill School of Medicine, chief, Plasma Cell Disorders Program, director, clinical research in hematologic malignancies, Levine Cancer Institute, discusses the impact of minimal residual disease (MRD) on clinical practice.
Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses the future of prostate cancer research.
Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.
Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.
Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses competing strategies in treating patients with relapsed multiple myeloma.
Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma.
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.
Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the promise of immunotherapy in the treatment of patients with HER2-positive breast cancer.
Xiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.
Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.
Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the approval process for biosimilars.
Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the treatment of pediatric patients with high-risk neuroblastoma.
Alessandro D. Santin, MD, professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses the impact of trastuzumab (Herceptin) in patients with uterine serous carcinoma.
Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses biosimilars in breast cancer.
Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.
Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses surgical options for the treatment of patients with newly-diagnosed ovarian cancer.
Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the WINS and WHEL trials in patients with breast cancer.
Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.
Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.
Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses the use of CDK 4/6 inhibitors in mantle cell lymphoma.
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.
Bradley J. Monk, MD, professor and director, Division of Gynecologic Oncology, Creighton University School of Medicine, Arizona Oncology, discusses combination approaches in patients with ovarian cancer.
Nitya Nathwani, MD, assistant clinical professor, Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the standard of care in patients with newly diagnosed multiple myeloma.
Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the treatment approach for patients with high-risk multiple myeloma.
Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.
Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery and Oncology, Johns Hopkins Medicine, discusses the treatment of patients with nasopharyngeal carcinoma.
Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with solid tumors.
H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation
Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses resistance mutations in patients with non–small cell lung cancer (NSCLC).
Mike Janicek, MD, medical director, Division of Genetics, Arizona Oncology, discusses the use of genetic testing in patients with ovarian cancer.
